The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 501–600 of 1,000
Moriyama, E., Nagasu, S., Tanaka, T., Shimotsuura, Y., Ono, T., Umeno, H., Akiba, J., Kawahara, A., Fujita, F., Kawaguchi, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247435 · Cited by 9
de Castro, J. V. A., dos Santos, P. J. S., Mantoan, H., Baiocchi, G., Bovolim, G., Torrezan, G. T., Corassa, M. P., Nascimento, A. G., Brot, M. D., Costa, F. D., et al. (2023) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000957 · Cited by 9
An update on pharmacotherapies for colorectal cancer: 2023 and beyond
Zhu, M., & Benson, A. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2304654 · Cited by 9
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?
Ricciuti, B., & Awad, M. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000489 · Cited by 9
Sánchez, M. D. C., Galán‐Gómez, V., Urgellés, A. S., de Sabando, D. P. L., Rubio, P., Martínez, L., Gamarra, E. A., Pozo‐Kreilinger, J. J., Regojo, R. M., López‐Gutiérrez, J. C., et al. (2021) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2021.1889730 · Cited by 9
Chen, W., Liu, D., Liu, P., Kong, Z., Wang, Y., Wang, Y., & Ma, W. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.12 · Cited by 9
Delaye, M., Ibadioune, S., Julié, C., Marin, C., Peschaud, F., Lupinacci, R. M., Vacher, S., Ahmanache, L., Antonio, S., Schnitzler, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.024 · Cited by 9
Pfaff, E., de Beaumais, T. A., Marchais, A., van Tilburg, C. M., Blattner-Johnson, M., Dirksen, U., Øra, I., Geoerger, B., Schleiermacher, G., Pfister, S. M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00417 · Cited by 9
Self-citationHamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01781-y · Cited by 8
Liu, Q., Chen, Y., Hu, Y., & Yang, J. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100771 · Cited by 8
Cherri, S., Libertini, M., Noventa, S., Oneda, E., Meriggi, F. A., & Zaniboni, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062522 · Cited by 8
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Yamada, D., Kobayashi, S., Doki, Y., & Eguchi, H. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02761-x · Cited by 8
Novel Therapeutics for Advanced Differentiated Thyroid Cancer
Lieberman, L., & Worden, F. P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.019 · Cited by 8
Raman, R., Ramamohan, V., Rathore, A. S., Jain, D., Mohan, A., & Vashistha, V. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13802 · Cited by 8
Aguiar, P. N., Matsas, S., Dienstmann, R., & Ferreira, C. G. (2023) · Personalized Medicine · doi:10.2217/pme-2022-0008 · Cited by 8
Drug development and evidence for lung cancer targeted therapy in Eastern Asia
Liu, S. M., Jin, Z., Deng, J., Zhong, S.-M., Ahn, M., Horinouchi, H., Li, Y., & Wu, Y.-L. L. C. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101090 · Cited by 8
Molecular landscape of salivary gland malignancies. What is already known?
Pikul, J., & Rzepakowska, A. (2024) · Współczesna Onkologia · doi:10.5114/wo.2024.144288 · Cited by 8
Valerio, L., & Matrone, A. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002291 · Cited by 8
Shehri, Z. S. A., & Alshehri, F. F. (2025) · Crystals · doi:10.3390/cryst15050383 · Cited by 8
Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice
Jacobs, C., & Lapeire, L. (2021) · Diagnostics · doi:10.3390/diagnostics11030512 · Cited by 8
Development of Tissue-Agnostic Treatments for Patients with Cancer
Lemery, S. J., Fashoyin‐Aje, L. A., Marcus, L. J., Casak, S. J., Schneider, J. A., Theoret, M. R., Kluetz, P. G., Pazdur, R., & Beaver, J. A. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060921-021828 · Cited by 8
Lazzari, C., Pecciarini, L., Doglioni, C., Pedica, F., Gajate, A. M. S., Bulotta, A., Gregorc, V., & Cangi, M. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038774 · Cited by 8
Chu, Y. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2026.06.005 · Cited by 8
Stockley, T. L., Lo, B., Box, A. H., Corredor, A., DeCoteau, J. F., Desmeules, P., Feilotter, H. E., Grafodatskaya, D., Greer, W. L., Hawkins, C. E., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.12.004 · Cited by 8
TrkA Co-Receptors: The Janus Face of TrkA?
Trouvilliez, S., Lagadec, C. H., & Toillon, R. (2023) · Cancers · doi:10.3390/cancers15071943 · Cited by 8
Kim, S., Cha, Y., Lim, Y., Roh, H., Kang, J., Lee, K., Kim, M. J., Park, J. W., Ryoo, S., Kim, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34558 · Cited by 8
Lassen, U., Bokemeyer, C., García‐Foncillas, J., Italiano, A., Vassal, G., Paracha, N., Marian, M., Chen, Y., Linsell, L., & Abrams, K. R. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00651 · Cited by 8
Offer, K., McGuire, M. T., Song, K., Goldfischer, M., Davare, M. A., Corless, C. L., Beadling, C., Neff, T. L., Cox, M. C., Raju, S. G., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00065 · Cited by 8
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
Lemelle, L., Guillemot, D., Hermann, A.-L., Gauthier, A., Carton, M., Corradini, N., Rome, A., Berlanga, P., Jourdain, A., Cardine, A. M., et al. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236305 · Cited by 8
Self-citationCanadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study
Hyrcza, M. D., Martins-Filho, S. N., Spatz, A., Wang, H., Purgina, B., Desmeules, P., Park, P. C., Bigras, G., Jung, S., Cutz, J., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100384 · Cited by 8
Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1
Kikuchi, Y., Shimada, H., Hatanaka, Y., Kinoshita, I., Ikarashi, D., Nakatsura, T., Kitano, S., Naito, Y., Tanaka, T., Yamashita, K., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02430-x · Cited by 8
Kubota, Y., Kawano, M., Iwasaki, T., Itonaga, I., Tsumura, H., Kaku, N., & Tanaka, K. (2023) · Medicine · doi:10.1097/md.0000000000036232 · Cited by 8
Zhou, J., Du, H., & Cai, W. (2024) · Translational Pediatrics · doi:10.21037/tp-23-557 · Cited by 8
Kumar, M., Fatima, Z. H., Goyal, P., & Qayyumi, B. N. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_284_23 · Cited by 8
Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned
Hogervorst, M. A., van Hattem, C., Sonke, G. S., Mantel-Teeuwisse, A. K., Goettsch, W., & Bloem, L. T. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104031 · Cited by 8
Progress in histology specific treatments in soft tissue sarcoma
Redaelli, S., Merlini, A., Khan, M. U., & Gronchi, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2384584 · Cited by 8
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin, F., Sokol, E. S., Vasan, N., Pavlick, D. C., Huang, R. S. P., Pelletier, M., Levy, M. A., Pusztai, L., Lacy, J., Zhang, J. Y., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae259 · Cited by 8
Carter‐Febres, M., Schneller, N., Fair, D. B., Solomon, D. A., Perry, A., Roy, A., Linscott, L. L., Alashari, M., Kestle, J. R. W., & Bruggers, C. S. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001983 · Cited by 8
Prabhash, K., Kapoor, A., Noronha, V., Chougule, A., Chandrani, P., Shetty, O. A., Patil, V. M., Joshi, A., Menon, N. S., Bal, M. M., et al. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_258_20 · Cited by 8
Lukas, R. V., & Mrugała, M. M. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000942 · Cited by 8
Sholl, L. M., Zheng, M., Nardi, V., & Hornick, J. L. (2021) · Histopathology · doi:10.1111/his.14351 · Cited by 8
Scheipl, S., Brčić, I., Moser, T., Fischerauer, S., Riedl, J. M., Bergovec, M., Smolle, M. A., Posch, F., Gerger, A., Pichler, M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029125 · Cited by 8
The oncogenic roles of NTRK fusions and methods of molecular diagnosis
Aref‐Eshghi, E., Lin, F., Li, M. M., & Zhong, Y. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.10.005 · Cited by 8
Yau, D. T., Lacambra, M. D., Chow, C., & To, K. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23024 · Cited by 8
Rakheja, D., Park, J. Y., Fernandes, N. J., Watt, T. C., Laetsch, T. W., & Collins, R. R. J. (2022) · International Journal of Surgical Pathology · doi:10.1177/10668969221080072 · Cited by 8
Self-citationClaerhout, S., Lehnert, S., Borght, S. V., Spans, L., Dooms, C., Wauters, E., Vansteenkiste, J., Weynand, B., Deraedt, K., Bourgain, C., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.013 · Cited by 8
Kato, A., Naitoh, I., Naiki‐Ito, A., Hayashi, K., Okumura, F., Fujita, Y., Sano, H., Nishi, Y., Miyabe, K., Inoue, T., et al. (2022) · Pancreas · doi:10.1097/mpa.0000000000002032 · Cited by 8
Hines, J. B., Bowar, B., Levine, E. E., Esposito, A., Garassino, M. C., & Bestvina, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119429 · Cited by 8
Pan-Cancer Molecular Biomarkers
Dong, F. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.012 · Cited by 8
Biliary tract cancers: advances in diagnostic and management
Gutmans, J., & Mechahougui, H. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002328 · Cited by 7
Mohammad, S. F. H., van der Pol, H., Vrdoljak, E., Lassen, U., Ojamaa, K., Jalkanen, K., Verlingue, L., Stenzinger, A., Patócs, A., Curigliano, G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105872 · Cited by 7
Keller-Evans, R. B., Lee, J., Allen, J. M., Zhong, L., Gjoerup, O. V., Ross, J. S., Gascó, A., & Huang, R. S. P. (2026) · The Oncologist · doi:10.1093/oncolo/oyag001 · Cited by 7
Olsen, M. R., Denu, R. A., Lyon, J. B., Gulliver, J. M., Capitini, C. M., & DeSantes, K. B. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002358 · Cited by 7
Stravodimou, A., & Voutsadakis, I. A. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i2.135 · Cited by 7
Neue Therapieansätze für Speicheldrüsenmalignome
Nachtsheim, L., Prinz, J., Arolt, C., Quaas, A., Meyer, M. F., Klußmann, J. P., & Wolber, P. (2022) · Laryngo-Rhino-Otologie · doi:10.1055/a-1792-2246 · Cited by 7
Identification of barriers to implementation of precision oncology in patients with rare cancers
Takamizawa, S., Koyama, T., Sunami, K., Sudo, K., Hirata, M., Kubo, T., Tao, K., Cho, H., Narita, Y., Kato, K., et al. (2024) · Cancer Science · doi:10.1111/cas.16165 · Cited by 7
Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
Percy, C., Schubert, T., Galant, C., Kirchgesner, T., & Mazzeo, F. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3878 · Cited by 7
Thorwarth, A., Haase, K., Röefzaad, C., Pajtler, K. W., Schramm, K., Hauptmann, K., Behnke, A., Vokuhl, C., Elgeti, T., Gratopp, A., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00283 · Cited by 7
Hernández, A., Muñoz-Mármol, A. M., Esteve‐Codina, A., Alameda, F., Carrato, C., Pineda, E., Arpí-LLucià, O., Martinez‐García, M., Mallo, M., Gut, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18608-8 · Cited by 7
Faure‐Conter, C., Calaminus, G., Nicholson, J. C., Idbaïh, A., Hoang‐Xuan, K., Vasiljevic, A., Morana, G., Szathmári, A., Ajithkumar, T., & Frappaz, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971697 · Cited by 7
Yokota, T., Yukino, H., Doi, M., & Ohori, H. (2023) · Head & Neck · doi:10.1002/hed.27346 · Cited by 7
McMahon, D. J., McLaughlin, R. A., & Naidoo, J. (2024) · Cancers · doi:10.3390/cancers16030527 · Cited by 7
Bokemeyer, C., Vassal, G., Italiano, A., Cuesta, E. A. D. L., Hiemeyer, F. J., Fellous, M. M., & Marian, M. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00089 · Cited by 7
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma
Fabregat-Franco, C., Castet, F., Castillo, G., Salcedo, M., Sierra, A., López-Valbuena, D., Pando, E., Tian, T. V., & Macarulla, T. M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104480 · Cited by 6
Bahng, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1713123 · Cited by 6
Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma
Sacdalan, D. B., Mendoza, M. J., Vergara, J. P., Catedral, L. I. G., Ting, F. I. L., Leones, L. M. B., Berba, C. M., & Sacdalan, D. L. (2020) · Medical Oncology · doi:10.1007/s12032-020-01432-3 · Cited by 6
Elghawy, O., Barsouk, A. A., Heidlauf, A., Chen, S., Cohen, R. B., & Sun, L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae158 · Cited by 6
Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma
Yuan, H., Wang, Y., Li, N., Wu, L., & Yao, H. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03415-3 · Cited by 6
Espósito, A., Crimini, E., Criscitiello, C., Belli, C., Scafetta, R., Scalia, R., Castellano, G., Giordano, E., Katrini, J., Ascione, L., et al. (2024) · Cancers · doi:10.3390/cancers16244252 · Cited by 6
Yang, X., Li, X., Yan, J., Liu, Y., Yin, J., Shao, W., Lu, Y., & Xue, J. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7070 · Cited by 6
Wallen, Z. D., Tierno, M. B., Schnettler, E. K., Roos, A., Green, M. F., Amoah, K. A., Previs, R. A., Hastings, S. M., Pabla, S., Jensen, T. J., et al. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1550706 · Cited by 6
Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment
Teleanu, M., Schneider, A., Ball, C. R., Leber, M. F., Stange, C., Krieghoff‐Henning, E., Beck, K., Heilig, C. E., Kreutzfeldt, S., Küster, B., et al. (2025) · Biomolecules · doi:10.3390/biom15050693 · Cited by 6
Patel, H. B., Dave, R. H., Vadariya, S., & Hirpara, H. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70150 · Cited by 6
Histology‐based molecular profiling improves mutation detection for advanced thyroid cancer
Eszlinger, M., Khalil, M., Gillmor, A. H., Huang, H., Stewardson, P., McIntyre, J. B., Morrissy, A. S., & Paschke, R. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22949 · Cited by 6
Rao, S. S., Gahlot, U. S., Dulawat, S. S., Vyas, R., Ameta, K. L., & Verma, B. L. (2003) · Afinidad · Cited by 6
Diagnosis and management of TRK fusion cancer
Kummar, S. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.88834 · Cited by 6
Self-citationVera, R., de Andrés, C. I., Adeva, J., Pérez‐Rojas, J., Alfonso, P. G., Rodriguez-Gil, Y., Macarulla, T. M., Piñol, T. S., Mondéjar, R., & Madrigal-Rubiales, B. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02873-0 · Cited by 6
Molecular Targets and Therapies for Ampullary Cancer
Patel, M. A., Kratz, J. D., Carlson, A. S., Ascencio, Y. O., Kelley, B. S., & LoConte, N. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7051 · Cited by 6
Yan, N., Zhang, H., Guo, S., Zhang, Z., Xu, Y., Xu, L., & Li, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1353491 · Cited by 6
Ewongwo, A. N., Hui, C., & Moding, E. J. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.12.002 · Cited by 6
Zhang, W., Tian, S., Li, X., Chen, Y., Wang, X., Zhang, Y., Lv, L., Li, Y., Shi, H., & Bai, C. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.03.005 · Cited by 6
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Алексахина, С. Н., Ivantsov, A. O., & Имянитов, Е. Н. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074094 · Cited by 6
Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?
El-Sayed, M. M., Bianco, J. R., Li, Y., & Fábián, Z. (2024) · Cells · doi:10.3390/cells13121071 · Cited by 6
Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions
Netto, D., Frizziero, M., Foy, V., McNamara, M. G., Backen, A. C., & Hubner, R. A. (2024) · Current Oncology · doi:10.3390/curroncol31090385 · Cited by 6
Torresan, S., Bortolot, M., Carlo, E. D., Bertoli, E., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020554 · Cited by 6
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Kim, Y., Song, J., Kim, N., & Sim, T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00881b · Cited by 6
TRK inhibitors: managing on-target toxicities
Lim, J. S. J., & Tan, D. S. P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.010 · Cited by 6
AMM : entrectinib et larotrectinib – cancers avec fusion NTRK
Delaye, M., & Rodrigues, M. J. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.09.009 · Cited by 6
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Toma, A. D., Russo, G. L., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103299 · Cited by 6
Új célzott terápiás lehetőség az onkológiában: tropomiozin receptor-tirozin-kináz gátlók
Kiss, É., & Pápai, Z. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32183 · Cited by 6
Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
Hampel, H. J., Lista, S., Caruso, G., Nisticò, R., Piccioni, G., Mercuri, N. B., Giorgi, F. S., Ferrarelli, F., Lemercier, P., Caraci, F., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201095701 · Cited by 6
Moati, É., Overman, M. J., & Zaanan, A. (2022) · Cancers · doi:10.3390/cancers14051137 · Cited by 6
Children's Oncology Group's 2023 blueprint for research: Rare tumors
Schultz, K. A. P., Chintagumpala, M., Piao, J., Chen, K. S.-M., Gartrell, R. D., Christison-Lagay, E. R., Berry, J. L., Shah, R., & Laetsch, T. W. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30574 · Cited by 6
Self-citationComplete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
Frehner, L., Haefliger, S., Cerciello, F., Grob, T. J., & Schmid, S. (2023) · Case Reports in Oncology · doi:10.1159/000533572 · Cited by 6
Impact of tissue-agnostic approvals on management of primary brain tumors
Ahluwalia, M. S., Khosla, A. A., Ozair, A., Gouda, M. A., & Subbiah, V. (2024) · Trends in cancer · doi:10.1016/j.trecan.2023.11.005 · Cited by 6
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Tropomyosin receptor kinases in sarcomas – of joy and despair
Dieckmann, N., Schildhaus, H., & Bauer, S. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000752 · Cited by 6
Canadian consensus on TRK‐inhibitor therapy for NTRK fusion‐positive sarcoma
Simmons, C. E., Deyell, R. J., MacNeill, A. J., Vera-Badillo, F., Smrke, A., Razak, A. R. A., Banerji, S. O., McLeod, D., & Noujaim, J. C. (2021) · International Journal of Cancer · doi:10.1002/ijc.33723 · Cited by 6
Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs
Kauffmann-Guerrero, D. E., & Tufman, A. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000806 · Cited by 6
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
